New reports on picoplatin from Poniard
US-based Poniard Pharmaceuticals has presented encouraging safety data from a Phase I dose-escalation study of picoplatin for the treatment of colorectal cancer.
The data presented at the 2008 Gastrointestinal Cancers Symposium included safety data from a Phase I study of picoplatin in combination with 5-fluorouracil (5FU) and leucovorin (LV) as a first-line treatment for metastatic colorectal [...]